# Parker Institute for Cancer Immunotherapy

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/parker-institute-for-cancer-immunotherapy/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 82.6 |
| Citations | 562,976 |
| City | San Francisco |
| Country | US |
| Description | Parker Institute for Cancer Immunotherapy is a research organisation in San Francisco, US. OpenAlex records 2,373 works and 562,976 citations for it. 595 researchers list it as their most recent affiliation. |
| Homepage | https://www.parkerici.org/ |
| OpenAlex ID | https://openalex.org/I4210109986 |
| Region | California |
| Researchers | 595 |
| ROR ID | https://ror.org/0184qbg02 |
| Type | facility |
| Works | 2,373 |

## University collaborators

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

## University papers

Showing 12 of 44.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial](https://scholariq.org/papers/t-cells-expressing-cd19-chimeric-antigen-receptors-for-acute-lymphoblastic/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1](https://scholariq.org/papers/tumor-regression-in-patients-with-metastatic-synovial-cell-sarcoma-and-melanoma/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy](https://scholariq.org/papers/cd22-targeted-car-t-cells-induce-remission-in-b-all-that-is-naive-or-resistant/)
- [A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging](https://scholariq.org/papers/a-structured-tumor-immune-microenvironment-in-triple-negative-breast-cancer/)
- [First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)

## University top topics

Showing 8 of 25.

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)
- [Single-cell and spatial transcriptomics](https://scholariq.org/topics/single-cell-and-spatial-transcriptomics/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.